SAN DIEGO

Drug developer Vical Inc. said Thursday a drug aimed at preventing a potentially fatal virus in stem cell transplant patients showed positive results in a midstage study.

The company said the TransVax cytomegalovirus vaccine demonstrated sustained increases in cellular and antibody immune response in the final 12-month followup to an ongoing trial midstage study.

Cytomegalovirus can cause respiratory illness and is suppressed by the immune system in most people. But it can cause transplant rejection if it flares up when a transplant recipient's immune system is suppressed during recovery.

Shares rose 21 cents, or 5.6 percent, to $3.74 in premarket trading.


BW Extras

 

Most Popular Stories

  1. Three Types of People to Fire Immediately
  2. Lego Is for Girls
  3. Google's Spreading Tentacles of Influence
  4. Gatorade Goes Back to the Lab
  5. Impress Potential Investors in 12 Steps

RSS Feed: Most Read Stories

  1. Three Types of People to Fire Immediately
  2. Which Is America's Best City?
  3. Lego Is for Girls
  4. Top B-School Stories of 2011
  5. Professional Women and a Secure Retirement

RSS Feed: Most E-mailed Stories

  1. Facebook's Holocaust Controversy
  2. America's Best, Affordable Places to Raise Kids
  3. Bullpen Diaries

RSS Feed: Most Discussed Stories

Most Popular Multimedia

  1. Tuition-Free Colleges
  2. Twenty Tips for First-Time Managers
  3. The Best Design Schools in the World

RSS Feed: Most Popular Slide Shows

BW Mall - Sponsored Links

Buy a link now!